Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01128452 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of EVT 101 in Treatment-Resistant Depression
A Phase 2 study, sponsored by Janssen Research & Development.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT01128452 is a Phase 2 study that was terminated before completion, run by Janssen Research & Development. The registered enrollment target is 8 participants.
The verdict
NCT01128452, a Phase 2 study, was terminated before completion, sponsored by Janssen Research & Development.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study is a 4-week, randomized, double-blind, parallel-group, placebo-controlled monotherapy study in patients with treatment-resistant major depression. After confirmation of treatment-resistance in a prospective treatment period with citalopram, each patient will be treated with either EVT 101 once daily or placebo for 28 consecutive days.
Interventions
- DRUG Placebo
- DRUG EVT 101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2010-06 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01128452
The ClinicalTrials.gov registry entry for NCT01128452 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01128452 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01128452 about?
NCT01128452 is a clinical study titled "Safety and Efficacy of EVT 101 in Treatment-Resistant Depression". This study is a 4-week, randomized, double-blind, parallel-group, placebo-controlled monotherapy study in patients with treatment-resistant major depression. After confirmation of treatment-resistance in a prospective treatment period with citalopram, each patient will be treated with either EVT 101...
What is the current status of trial NCT01128452?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2010-06. Estimated completion is 2011-03.
What interventions are being tested in trial NCT01128452?
The interventions under investigation include: Placebo (DRUG), EVT 101 (DRUG).
Who is sponsoring clinical trial NCT01128452?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.